Design and experimental verification of novel angiotensin‐converting enzyme and dipeptidyl peptidase IV inhibitory peptides from <i>Ziziphus jujuba</i> peptide KALVAP
In summary, two new peptides, WALVAP and WPLVAP, were screened and exhibited excellent DPP-IV inhibitory activity. The results implied that the optimization strategy is feasible and can provide a reference for drug design. Thus WALVAP and WPLVAP could serve as potential drug candidates for patients with hypertension and diabetes mellitus. © 2025 Society of Chemical Industry.
Authors
- Xinchang Gao
- Yali Dang (ORCID: https://orcid.org/0000-0001-6853-4699)
- Yanli Wang (ORCID: https://orcid.org/0000-0001-7438-5001)
- Huan Wen
- Daodong Pan (ORCID: https://orcid.org/0000-0003-2935-9781)
- Kuo Dang
- Jing Lan (ORCID: https://orcid.org/0009-0004-3595-7467)
Institutions
- Ningbo University (CN)
Publication Details
- Journal
- Journal of the Science of Food and Agriculture
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1002/jsfa.70156
- Primary Topic
- Protein Hydrolysis and Bioactive Peptides
- Type
- article
- Field-Weighted Citation Impact
- 0.00